Advertisement

The Immune-Status in Patients with Bone and Soft-Tissue Sarcomas

  • R. Kotz
  • W. Rella
  • M. Salzer
Part of the Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer book series (RECENTCANCER, volume 54)

Abstract

As the sarcoma develops in most cases at a stage of life when there is sufficient immunity, namely during the first three decades, immunological testing of sarcoma-bearing patients is extremely interesting. A further reason for examining sarcoma patients is the rapid development of metastases in this illness. This suggests that observation of the development over a short period will suffice for an assessment of the prognosis (8, 16). If careful clinical examination 6 months after actual treatment does not reveal metastases, the chances of survival are considerably better than if metastases are discovered.

Keywords

Skin Test Stimulation Index Cytotoxicity Test Malignant Bone Tumor Sarcoma Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    AL-SARRAF, M., WONG, P., SARDESAI, S., VAITKEVICIUS, V.K.: Clinical immunologic responsiveness in malignant disease. Cancer 26, 262–268 (1970)PubMedCrossRefGoogle Scholar
  2. 2.
    BRUN, F.E.: Die kutan-allergische Spätreaktion auf 2, 4-Dinitro-chlorobenzol bei Krebspatienten unter zytostatischer Chemotherapie. Schweiz, med. Wschr. 101, 1235–1243 (1971)Google Scholar
  3. 3.
    COHEN, A.M., KETCHAM, A.S., MORTON, D.L.: Tumor-specific cellular cytotoxicity to human sarcomas: evidence for a cell-mediated host immune response to a common sarcoma cell-surface antigen. J. nat. Cancer Inst. 50, 585–589 (1973)PubMedGoogle Scholar
  4. 4.
    COLEY, W.B.: The treatment of inoperable sarcoma by bacterial toxins. Proc. roy. Soc. Surg. Sed. 3, 1 (1909)Google Scholar
  5. 5.
    EILBER, F.R., MORTON, D.L.: Impaired immunologic reactivity and recurrence following cancer surgery. Cancer, 25, 362–367 (1970)PubMedCrossRefGoogle Scholar
  6. 6.
    HELLSTRöM, I., HELLSTRöM, K.E., SJöGREN, H.O.: Demonstration of cell-mediated immunity to human neoplasms of various histological types. Int. J. Cancer 7, 1–16 (1971)PubMedCrossRefGoogle Scholar
  7. 7.
    HOLLINSHEAD, A.C., STEWART, H.M., HERBERMANN, R.B.: Delayed-hyper-sensitivity reactions to soluble membrane antigens of human malignant lung cells. J. nat. Cancer Inst. 52, 327–337 (1974)PubMedGoogle Scholar
  8. 8.
    KOTZ, R., SALZER-KUNTSCHIK, M., ZWEYMüLLER, K., SALZER, M.: Therapy and prognosis of the Ewing-sarcoma. Öst. Z. Onkol. 1, 15–22 (1974)Google Scholar
  9. 9.
    KOTZ, R., RELLA, W.: Überprüfung der zellulären Abwehrlage bei Patienten mit Knochentumoren. Verh. dtsch. Ges. Path. 58. 471–474 (1974)Google Scholar
  10. 10.
    MARCOVE, R.C., MIKé, VALERIE, HUVOS, A.G., SOUTHAM, C.M., LEVIN, A.G.: Vaccine trials for osteogenic sarcoma. A preliminary report. Ca. Cancer J, Clin. 23, 74–80 (1973)CrossRefGoogle Scholar
  11. 11.
    MAVLIGIT, G.M., AMBUS, U., GUTTERMAN, J.U., HERSH, E.M., MCBRIDE, C.M.: Antigen solubilized from human solid tumours: lymphocyte stimulation and cutaneous delayed hypersensitivity. Nature New Biol. 243, 188–190 (1973)PubMedGoogle Scholar
  12. 12.
    MENDOZA, C.B., MOORE, G.E., WATNE, A.L., HIRAMOTO, R., JURAND, J.: Immunologic response following homologous transplantation of cultured human tumor cells in patients with malignancy. Surgery 64, 897–900 (1968)PubMedGoogle Scholar
  13. 13.
    NADLER, S.H., MOORE, G.E.: Immunotherapy of malignant disease. Arch. Surg. 99, 376–381 (1969)PubMedCrossRefGoogle Scholar
  14. 14.
    PERLMANN, P., O’TOOLE, D., UNSGAARD, B.: Cell-mediated immune mechanism of tumor cell destruction. Fed. Proc. 32, 153–155 (1973)PubMedGoogle Scholar
  15. 15.
    PERPER, R.J., ZEE, T.W., MICHELSON, M.M.: Purification of lymphocytes and platelets by gradient centrifugation. J. lab. clin. Med. 72, 842–848 (1968)PubMedGoogle Scholar
  16. 16.
    SALZER, M., SALZER-KUNTSCHIK, M., ZHUBER, K., PRICE, C.H.G., WIL-LERT, H.G., IMMENKAMP, M., GROH, P., MATEJOVSKY, Z., KEYL, W.: Therapie und Prognose des kindlichen Osteosarkoms. Z. Orthop. (in press)Google Scholar
  17. 17.
    VáNKY. F., STJERNSWäRD, J., NILSONNE, U.: Cellular immunity to human sarcoma. J. nat. Cancer Inst. 46. 1145–1151 (1971)PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1976

Authors and Affiliations

  • R. Kotz
  • W. Rella
  • M. Salzer

There are no affiliations available

Personalised recommendations